This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ohta, T. Articles by Hirohashi, S. Search for Related Content PubMed PubMed Citation Articles by Ohta, T. Articles by Hirohashi, S.

Loss of Keap1 Function Activates Nrf2 and Provides Advantages for Lung Cancer Cell Growth

¹ Center for Medical Genomics, ² Biology Division, ³ Pathology Division, and ⁴ Cancer Genomics Project, National Cancer Center Research Institute; ⁵ Department of Computational Biology, Tokyo Medical and Dental University, Tokyo, Japan; ⁶ Center for Tsukuba Advanced Research Alliance and Japan Science and Technology Agency-Exploratory Research for Advanced Technology Environmental Response Project, University of Tsukuba, Tsukuba, Japan; and ⁷ Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan

Requests for reprints: Tsutomu Ohta, Center for Medical Genomics, National Cancer Center Research Institute, 5-1-1 Tsukiji Chuo-ku, Tokyo 104-0045, Japan. Phone: 81-3-3542-2511; Fax: 81-3-3248-1631; E-mail: cota{at}gan2.res.ncc.go.jp.

Key Words: KEAP1 • NRF2 • lung cancer • cell growth • cytoprotective genes

Oxidative and electrophilic stresses are sensed by Keap1, which activates Nrf2 to achieve cytoprotection by regulating the expression of drug-metabolizing and antioxidative stress enzymes/proteins. Because oxidative and electrophilic stresses cause many diseases, including cancer, we hypothesized that an abnormality in the Nrf2-Keap1 system may facilitate the growth of cancer cells. We sequenced the KEAP1 gene of 65 Japanese patients with lung cancer and identified five nonsynonymous somatic mutations at a frequency of 8%. We also identified two nonsynonymous somatic KEAP1 gene mutations and two lung cancer cell lines expressing KEAP1 at reduced levels. In lung cancer cells, low Keap1 activity (due to mutations or low-level expression) led to nuclear localization and constitutive activation of Nrf2. The latter resulted in constitutive expression of cytoprotective genes encoding multidrug resistance pumps, phase II detoxifying enzymes, and antioxidative stress enzymes/proteins. Up-regulation of these target genes in lung cancer cells led to cisplatin resistance. Nrf2 activation also stimulated growth of lung cancer–derived cell lines expressing KEAP1 at low levels and in mutant cell lines and in Keap1-null mouse embryonic fibroblasts under homeostatic conditions. Thus, inhibition of NRF2 may provide new therapeutic approaches in lung cancers with activation of Nrf2. [Cancer Res 2008;68(5):1303–9]

This article has been cited by other articles:

				H. Kurokawa, H. Motohashi, S. Sueno, M. Kimura, H. Takagawa, Y. Kanno, M. Yamamoto, and T. Tanaka Structural Basis of Alternative DNA Recognition by Maf Transcription Factors Mol. Cell. Biol., December 1, 2009; 29(23): 6232 - 6244. [Abstract] [Full Text] [PDF]

				A.K. MacLeod, M. McMahon, S. M. Plummer, L. G. Higgins, T. M. Penning, K. Igarashi, and J. D. Hayes Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds Carcinogenesis, September 1, 2009; 30(9): 1571 - 1580. [Abstract] [Full Text] [PDF]

				S. J. Salipante, M. E. Mealiffe, J. Wechsler, M. M. Krem, Y. Liu, S. Namkoong, G. Bhagat, T. Kirchhoff, K. Offit, H. Lynch, et al. Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells PNAS, September 1, 2009; 106(35): 14920 - 14925. [Abstract] [Full Text] [PDF]

				M. Loignon, W. Miao, L. Hu, A. Bier, T. A. Bismar, P. J. Scrivens, K. Mann, M. Basik, A. Bouchard, P. O. Fiset, et al. Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy Mol. Cancer Ther., August 1, 2009; 8(8): 2432 - 2440. [Abstract] [Full Text] [PDF]

				S. Homma, Y. Ishii, Y. Morishima, T. Yamadori, Y. Matsuno, N. Haraguchi, N. Kikuchi, H. Satoh, T. Sakamoto, N. Hizawa, et al. Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung Cancer Clin. Cancer Res., May 15, 2009; 15(10): 3423 - 3432. [Abstract] [Full Text] [PDF]

				P. J. Barnes Future Treatments for Chronic Obstructive Pulmonary Disease and Its Comorbidities Proceedings of the ATS, December 1, 2008; 5(8): 857 - 864. [Abstract] [Full Text] [PDF]

				A. Singh, S. Boldin-Adamsky, R. K. Thimmulappa, S. K. Rath, H. Ashush, J. Coulter, A. Blackford, S. N. Goodman, F. Bunz, W. H. Watson, et al. RNAi-Mediated Silencing of Nuclear Factor Erythroid-2-Related Factor 2 Gene Expression in Non-Small Cell Lung Cancer Inhibits Tumor Growth and Increases Efficacy of Chemotherapy Cancer Res., October 1, 2008; 68(19): 7975 - 7984. [Abstract] [Full Text] [PDF]

				P. J. Barnes Defective Antioxidant Gene Regulation in COPD: A Case for Broccoli Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 552 - 554. [Full Text] [PDF]

				D. Malhotra, R. Thimmulappa, A. Navas-Acien, A. Sandford, M. Elliott, A. Singh, L. Chen, X. Zhuang, J. Hogg, P. Pare, et al. Decline in NRF2-regulated Antioxidants in Chronic Obstructive Pulmonary Disease Lungs Due to Loss of Its Positive Regulator, DJ-1 Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 592 - 604. [Abstract] [Full Text] [PDF]

				T. Shibata, T. Ohta, K. I. Tong, A. Kokubu, R. Odogawa, K. Tsuta, H. Asamura, M. Yamamoto, and S. Hirohashi Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy PNAS, September 9, 2008; 105(36): 13568 - 13573. [Abstract] [Full Text] [PDF]